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The discovery and therapeutic use of antibiotics made a major contribution to the reduction
of human morbidity and mortality. However, the growing resistance to antibiotics has
become amatter of huge concern. In this studywe aimed to develop an innovative approach
to treat bacterial infections utilizing two components: the human antibacterial peptide β-
defensin-3 (BD3) and the bacterial protein ﬂagellin (F). This combination was designed to
provide an efﬁcient weapon against bacterial infections with the peptide killing the bacteria
directly, while the ﬂagellin protein triggers the immune system and acts against bacteria
escaping from the peptide’s action.We designed, expressed and puriﬁed the fusion protein
ﬂagellin BD3 (FBD3) and its two components, the F protein and the native BD3 peptide.
FBD3 fusion protein and native BD3 peptide had antibacterial activity in vitro against various
bacterial strains. FBD3 and F proteins could also recognize their receptor expressed on
target cells and stimulated secretion of IL-8. In addition, F and FBD3 proteins had a partial
protective effect in mice infected by pathogenic Escherichia coli bacteria that cause a lethal
disease. Moreover, we were able to show partial protection of mice infected with E. coli
using a ﬂagellin sequence from Salmonella.We also explored ﬂagellin’s basic mechanisms
of action, focusing on its effects on CD4+ T cells from healthy donors. We found that F
stimulation caused an increase in the mRNA levels of the Th1 response cytokines IL12A
and IFNγ. In addition, F stimulation affected its own receptor.
Keywords: antibacterial peptide β-defensin-3 (BD3), flagellin (F), fusion protein (FBD3), bacterial infection,
antibacterial activity,TLR5 receptor, human CD4+T cells
INTRODUCTION
The effectiveness of antibiotics, used since Fleming’s discovery in
1927 to ﬁght bacterial infections, has decreased in recent years due
to the emergence of “superbugs” – bacterial strains resistant to all
known antibiotic treatments. This is considered to be one of the
world’s most critical health problems, and is believed to be a con-
sequence of the frequent overuse of antibiotic agents. Moreover,
according to FDA reports, the development and research of new
antibiotic drugs has declined in the recent years (Taubes, 2008).
For these reasons, the design of new strategies for the development
of anti-bacterial agents has become of major interest.
One of the most promising ﬁelds in medicine today is biologi-
cal drugs. Among these drugs, fusion proteins are considered to be
a powerful tool for targeted treatment of diseases such as cancers,
autoimmune diseases or metabolic diseases (Lorberboum-Galski,
2011). Here, for the ﬁrst time, we used this powerful tool as a new
approach to treating bacterial infections, utilizing two compo-
nents: the human antibacterial peptide β-defensin-3 (BD3) that
belongs to the innate immune system and the bacterial protein
ﬂagellin that induces the immune system. This combination is
hypothesized to provide an efﬁcient weapon to ﬁght and com-
bat bacterial infections; while the peptide will kill the bacteria
directly, the ﬂagellin, recognized by its receptor-TLR5, will trigger
the immune system and locally act against the residual bacteria
that succeed in escaping the peptide’s action.
To test this conceptweused two strategies; the ﬁrstwas to design
a fusion protein composed of both molecules – one moiety being
the ﬂagellin protein and the other an antibacterial peptide – fused
at the complementary DNA (cDNA) level. The second strategy
was to use the two components individually.
The innate immune system is the body’s ﬁrst line of defense
against various pathogens. The recognition of invader microbes
by the host is done through a series of receptors among them the
Toll-like receptor (TLR) family is the best characterized (Kawai and
Akira, 2007). These receptors can recognize limited and highly
conserved sets of molecular structures produced by microor-
ganisms that are termed pathogen associated molecular patterns
(PAMPs; Mogensen, 2009). The recognition of a particular PAMP
by a speciﬁc TLR leads to a cascade that eventually causes acti-
vation of the transcription factor NFκB (Kawai and Akira, 2010).
TLR5 can recognize a site on the highly conserved bacterial protein
ﬂagellin (Andersen-Nissen et al., 2007). Flagellin has four globu-
lar domains: D0, D1, D2, and D3, with domain D1 containing
the highly conserved regions involved in ﬂagellin recognition and
signaling (Yonekura et al., 2003). The monomer form of ﬂagellin
induces TLR5 signaling (Smith et al., 2003).
One important component belonging to the innate immune
system is the antibacterial peptides. These peptides are highly
heterogeneous in sequence, length and structure but most of
them are small and positively charged with the ability to kill a
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broad-spectrum of bacteria, fungi, yeasts, and viruses (Jenssen
et al., 2006). One of the most promising antibacterial peptides
is the BD3; a 45-residue cationic peptide with an asymmet-
rical distribution of charged amino acids, mostly clustered at
the carboxyl-terminal region. BD3 shows a broad spectrum of
antibacterial activity against Gram-negative and Gram-positive
bacteria, including resistant strains (Shelburne et al., 2005).
To test our hypothesis, we chose the gene ﬂiC coding for
Salmonella typhimurium ﬂagellin, and as an antibacterial peptide
we used the gene coding for BD3. By fusing these two moieties
we obtained the fusion protein ﬂagellin BD3 (FBD3). We also
cloned and produced the two components separately; the native
BD3 peptide (nBD3) and the ﬂagellin protein (F).
The new antibacterial fusion protein and the separate recombi-
nant proteins/peptides were tested for their ability to target and kill
bacteria in both in vitro and in vivo models. We also explored basic
mechanisms in which ﬂagellin is involved, focusing on its effects
on the subpopulation of CD4+ T cells from healthy donors.
MATERIALS AND METHODS
CELL CULTURES AND BACTERIAL STRAIN
Cell cultures
Colo-205, human colon cancer carcinoma cells (ATCC, USA, cat-
alog no. CCL-222) and Bjab-human, Burkitt’s lymphoma cells B
blast, (kindly provided by Hanna Ben-Bassat, Hadassah Medical
Center, Jerusalem) cell lines were grown in Roswell Park Memorial
Institute (RPMI) medium (Biological Industries, Beit-Haemek,
Israel) supplemented with 10% fetal bovine serum (HyClone,
Logan, UT, USA), 100 μg/ml penicillin/streptomycin and 2 mM
L-glutamine (Biological Industries).
Bacterial strains
Escherichia coli DH5 alpha, Salmonella typhimurium (ATCC
14028), E. coli (ATCC 25922) and Staphylococcus aureus (ATCC
6538) were obtained from ATCC (Manassas, VA, USA).
CONSTRUCTION OF PLASMIDS EXPRESSING FLAGELLIN AND
β-DEFENSIN-3 PROTEINS
Flagellin
To obtain the Salmonella ﬂagellin sequence total DNA from
Salmonella lysate was isolated and the ﬂagellin sequence (aa 1–
495) ﬂanked by Nde I/BamH I restriction sites was obtained by
polymerase chain reaction (PCR) using the following primers:
5′-CGCCATATGGCACAAGTCATTAAT-3′ (sense)
5′-CGGGATCCTTACGCAGTAAAGAGAG-3′ (antisense)
The PCR product cut with Nde I/BamH I was cloned into a
pET28 expression vector, cut with the same restriction enzymes,
so obtaining the pOS01 plasmid.
Flagellin β-defensin-3
To construct the fusion protein the same 5′ primer for ﬂagellin was
used (see Flagellin) with the following antisense primer to obtain
the ﬂagellin sequence:
5′-CGGGATCCACGCAGTAAAGAGAGGAC-3′ (antisense)
The PCR product cut with Nde I/BamH I was cloned into a Nde
I/BamH I cut pET28 expression vector. The next step was to obtain
the BD3 sequence ﬂanked with BamH I/Hind III. The cDNA for
human BD3 was obtained by RT-PCR, using RNA isolated from
fresh phytohaemagglutinin (PHA) activated human lymphocytes.
Total RNA was isolated and reverse transcribed into cDNA, using
a reverse transcription kit (Promega, Madison, WI, USA). The
BD3 (aa 1–45), ﬂanked by BamH I/Hind III restriction sites was
obtained by PCR using the following primers:
5′-CCCCATATGCAGAAATATTATTGCAGA-3′ (sense)
5′-CCCAAGCTTTTATTTCTTTCTTCGGCA-3′ (antisense)
The PCR product cut with BamH I/Hind III was cloned into
a cut pET28 expression vector downstream to ﬂagellin sequence
(see above), so obtaining the pOS03 plasmid.
Native β-defensin-3
To construct the native peptide the same cDNA and the
same 5′ primer for BD3 were used (see above) with the
following antisense primer to obtain the BD3 sequence:
5′-CCATGGGCATCATAAACACATTA-3′ (antisense). The PCR
product cut with Nde I/BamH I was cloned into a pET28 expres-
sion vector, cut with the same restriction enzymes so obtaining
the pOS04 plasmid. All the clones were conﬁrmed by sequencing
analysis.
PROTEIN EXPRESSION, PURIFICATION OF THE RECOMBINANT
PROTEINS AND ITS CHARACTERIZATIONS
Proteins expressions and puriﬁcations
Escherichia coli BL21-CodonPlus (λDE3) competent cells trans-
formed with the plasmids encoding the recombinant pro-
teins/peptide F,FBD3, andnBD3were incubated at 37◦C in a saline
lactose broth (SLB) medium containing kanamycin (50 μg/ml),
tetracycline (12.5 μg/ml), and chloramphenicol (34 μg/ml). At an
OD600 of 0.8, protein expressionwas induced by adding isopropyl-
beta-D-thiogalactopyranoside (IPTG, 1 mM ﬁnal concentration).
After 2hof incubation at 37◦C,the cellswere harvestedby centrifu-
gation (500 g for 15 min at 4◦C). For the puriﬁcation procedure
of F and FBD3, bacteria pellets were sonicated in binding buffer
[PBS – pH 7.4, 1 mM phenylmethylsulfonyl ﬂuoride (PMSF)
and 40 mM imidazole (Sigma-Aldrich, St. Louis, MO, USA)].
The suspensions were clariﬁed by centrifugation (35,000 g for
30 min at 4◦C), and the supernatants containing the recombinant
proteins were puriﬁed, using pre-equilibrated HiTrap chelating
HP columns (Amersham-Pharmacia Biotech, Uppsala, Sweden).
Columns were washed by stepwise addition of increasing imida-
zole concentrations. Finally, the target proteins were eluted with
elution buffer (PBS – pH 7.4 + 500 mM imidazole). FBD3 was
dialyzed against PBS, aliqoted and kept at −20◦C.
For the F protein, an additional puriﬁcation stepwas performed
to remove endotoxins. The puriﬁed F protein was dialyzed against
MES [(2-(N-morpholino)ethanesulfonic acid)] buffer (20 mM
Tris-HCl, pH 5.5) and loaded onto SP-Sepharose FF (1.5Å∼5 cm)
equilibratedwithMES buffer. The recombinant proteinwas eluted
with MES buffer supplemented with 0.5 M NaCl, dialyzed against
PBS aliqoted and kept at −20◦C.
For the puriﬁcation of nBD3, bacteria pellets were sonicated in
binding buffer (MES – pH 5.5, 1 mM PMSF and 0.1 M NaCl).
The suspensions were clariﬁed by centrifugation (35,000 g for
30 min at 4◦C), and the supernatants containing the recombi-
nant peptide were puriﬁed using SP-Sepharose FF (1.5Å∼5 cm)
pre-equilibrated with MES buffer. The recombinant peptide was
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eluted with MES buffer supplemented with 0.8 M NaCl. The puri-
ﬁed peptide was dialyzed against various buffers and found to be
highly active in 20 mM Tris pH −8.
Characterization of the fusion proteins
Determination of protein concentration. Protein concentration
was measured according to the Bradford method, using the Brad-
ford reagent and a standard curve of bovine serum albumin (BSA).
Protein concentration was determined at a wavelength of 595 nm.
Separation of proteins by electrophoresis. Samples from the vari-
ous protein fractions (5–20 μg protein/lane) were loaded on 12%
(w/v) SDS/PAGE gels for the proteins or tricine gel for the peptides
(Judd, 1994).
Western blot analysis. Proteins and peptides (5–20 μg pro-
tein/lane) were resolved respectively on 12% SDS-PAGE and
tricine gels and transferred onto an Immobilon-P transfer mem-
brane (Millipore, Bradford, PA, USA). Western blot analysis was
performed using either anti-His (Amersham-Pharmacia Biotech),
or anti-β defensin 3 (Santa-Cruz Biotechnology) antibodies at
1:20,000 or 1:200 dilution respectively, to identify the relevant
proteins/peptides. Primary antibody bindingwas detected by blot-
ting with a suitable secondary antibody conjugated to horseradish
peroxidase (HRP; 1:10,000). Band visualization was performed
using an enhanced chemiluminescence kit (EZ-ECL, Biologi-
cal Industries, Beit-Haemek, Israel) according to manufacturer’s
instructions.
ACTIVITY ASSAYS
Antibacterial activity assay
Glycerol stocks from various pathogenic bacteria were spread on
agar plates and incubated overnight at 37◦C. One colony from
the plate was removed to fresh Luria-Broth (LB) medium for
an overnight growing starter. The overnight bacterial starter was
diluted 1/100 with fresh LB medium and different amounts of the
tested proteins/peptide were added to the diluted bacteria and
then grown at 37◦C for 3 h. The growing bacteria were seri-
ally diluted and 5 μl from each dilution was plated on LB agar
plates. The LB agar plates were incubated at 37◦C overnight and
on the next day the number of colony forming units (CFU) was
determined.
Flagellin activity assay
Bjab or Colo-205 cells were seeded on 6-well plates. After 24 h
the fusion protein FBD3 (0.2–20 ng), the recombinant protein F
(0.1–12 ng), or GnRH-Cherry (20 ng) as a control protein were
added to the cells. After 4 h incubation the cell-free supernatants
were analyzed according to the manufacturer’s instructions for
human IL-8 content, using Human IL-8 ELIZA KIT II (BD
Biosciences San Diego, CA, USA). The wells were spectropho-
tometrically analyzed at 450 nm using a VersaMax microplate
reader (Molecular Devices). The concentration of each unknown
sample was determined according to a standard curve of IL-8
concentrations and analyzed using the four-parameter algorithm
on SoftMax Pro software (Molecular Devices Corporation, CA,
USA).
FLOW CYTOMETRY
To verify the amount of TLR5 expressed on the cell surface of
the various cell cultures (Colo-205, Bjab and CD4+ T cells),
the cells (0.5–1 × 106 cells in total) were washed twice with
PBS, centrifuged at 300 g for 5 min, resuspended in 50 μl of
the ﬂuorescence-activated cell sorting (FACS) buffer (3% FCS,
0.02% Azide in PBS), and incubated for 30 min at 4◦C with rab-
bit anti-TLR5 Ab (1:200; Alexis Plymouth Meeting, PA, USA).
The cells were washed twice with FACS buffer, resuspended
in 50 μl of the same buffer, and the human cell lines were
incubated with FITC-conjugated rabbit anti-goat secondary Ab
(Jackson ImmunoResearch Laboratories, Bar Harbor, ME, USA)
for 20 min at 4◦C. The cells were washed twice with FACS buffer,
resuspended in 0.5 ml PBS, and analyzed by FACScan (Bec-
ton Dickinson Immunocytometry Systems, San Jose, CA, USA)
using the CellQuest program. For the CD4+ T cells additional
staining was performed with anti-human CD4-PE-conjugated
(1:50; Serotec, Oxford, UK). The cells were washed twice with
FACS buffer, resuspended in 0.5 ml PBS, and analyzed by
FACScan.
ISOLATION OF PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCs)
FROM HEALTHY DONORS
The human peripheral blood mononuclear cells (PBMCs) from
healthy donors were isolated on a Ficoll–Isopaque gradient (d
1.077 Sigma-Aldrich, St. Louis, MO, USA). The isolated PBMCs
were then counted and checked for viability using Trypan blue.
To activate the lymphocytes, all mononuclear cells were grown
in RPMI 1640 supplemented with 10% (v/v) fetal calf serum,
2 mM L-glutamine, 100-units/ml penicillin, 100 μg/ml strepto-
mycin, 10 μM β-mercaptoethanol and with phytohemagglutinin
(PHA 20 μg/ml) for 3 days. The activated cells were washed and
resuspended in the presence of 10 units/ml of recombinant IL-2
(PeproTech EC Ltd., London, UK) to maintain cell viability. Naïve
lymphocytes were grown in RPMI 1640 supplemented with 10%
(v/v) fetal calf serum, 2 mM L-glutamine, 100 units/ml penicillin,
100 μg/ml streptomycin and 10 μM β-mercaptoethanol.
FLAGELLIN EXPERIMENTS
Experiments on isolated CD4+ T cells
CD4+ T cells were isolated from human fresh mononuclear cells
by CD4+ starting kit (Miltenyi BiotecAuburn, CA,USA) andwere
95–98% pure according to FACS analysis. Following puriﬁcation,
CD4+T cells (106 cells) were plated out and incubated in the pres-
ence or absence of the puriﬁed F protein (2 ng/ml), for 18 or 24 h,
once or three times. In some experiments the fresh mononuclear
cells were activated by PHA and were grown with IL2 (see above).
Following activation, CD4+ T cells were isolated with the same
kit and incubated in the presence or absence of the F protein as
described above.
Experiments on PBMCs cells
Peripheral blood mononuclear cells (107 cells) were seeded on
plates and incubated in the presence or absence of F protein
(2 ng/ml or 6 ng/ml) for 2, 6, 12, 24, or 36 h. Following incu-
bation the CD4+ T cells were separated using the CD4+ starting
kit (see above) and were 95–98% pure according to FACS analysis.
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Table 1 | Primers used for testing expression levels of specific genes by real time PCR.
Gene Location Product size Sequence
G6PD Exon 3/4 129 bp Forward 5′-CACCATCTGGTGGCTGTTC-3′
Exon 4 Backward 5′-TCACTCTGTTTGCGGATGTC-3′
IFNγ Exon 2/3 100 bp Forward 5′- TTGGAAAGAGGAGAGTGACAGAAA-3′
Exon 3 Backward 5′-CTTTTGGATGCTCTGGTCATCTTTA-3′
IL12A Exon 2 151 bp Backward 5′-GAATGTTCCCATGCCTTCAC-3′
Exon 2/3 Forward 5′-TCTAGAGTTTGTCTGGCCTTCTG-3′
IL4 Exon 3 278 bp Backward 5′-GCAGTTCCACAGGCACAAG-3′
Exon 4 Forward 5′-CTCTGGTTGGCTTCCTTCAC-3′
IL5 Exon 1/2 192 bp Backward 5′-GCCAATGAGACTCTGAGGATTC-3′
Exon 3 Forward 5′-CCCTTGCACAGTTTGACTCTC-3′
TLR5 Exon 3/4 261 bp Forward 5′-TGCTAGGACAACGAGGATCA-3′
Exon 4 Backward 5′-CAGGAAGGAATTCCAAACACA-3′
RNA ISOLATION AND REAL-TIME PCR
Total RNA was extracted from the various treated cells using the
High Pure RNA Isolation Kit (Roche, Germany). The RNA was
reverse transcribed using a Verso cDNA kit (Thermo Scientiﬁc,
Epson, Surrey, UK) using random primers. Real-time quantitative
PCR was performed on an ABI Prism 7500 HT sequence detec-
tion system using SYBR® Green methods (Applied Biosystems,
Foster City, CA, USA). All these steps were carried out according
to the manufacturer’s instructions. Speciﬁc gene expression was
normalized to that of the G6PD gene. Relative expression of IL4,
IL12A, IFNγ, and TLR5 mRNA levels in treated cells as compared
to control cells was calculated using the 2−Ct analysis (Applied
Biosystems). All samples were run in triplicate (Table 1).
IN VIVO MODEL
All the experiments were performed using 7–8 week old female
Balb/C mice in the speciﬁc pathogen-free unit of the Hadas-
sah Medical School (Ein Kerem, Jerusalem). For testing the
non-speciﬁc toxicity of F and FBD3, 5 or 10 μg of F or
20 μg of FBD3 were administered i.p. to 7–8 week old female
Balb/C mice. Mice were checked daily and weighed every 1 or
2 days.
To determine the CFU of pathogenic E. coli (ATCC 25922) that
was needed to cause mice death, a series of dilutions were made
and different concentrations of bacteria were injected i.p. into
mice in 200 μl of sterile PBS. To test the effect of F and FBD3 on
infected mice, 5 (eight mice) or 10 μg of F (10 mice) or 20 μg
(10 mice) of FBD3 were injected into 7–8 week old female Balb/C
mice. Four hours later 5 × 108 CFU/ml of E. coli bacteria (ATCC
25922) in 200 μl of sterile PBS were injected i.p. into these mice.
Mice were checked for mortality every day.
ETHIC STATEMENT
Fresh buffy coat human blood samples from healthy donors were
obtained according to the guidelines approved by the Hadas-
sah Hospital Ethics Committee (Jerusalem, Israel). All subjects
provided written informed consent.
All procedures involving mice were approved by the Hebrew
University of Jerusalem Institutional Animal Care and Use Com-
mittee, approval no. MD-07-10429-5. This study was conducted
in accordance with the NIH Guide for the Care and Use of
Laboratory Animals (NIH approval number OPRR-A01-5011).
The mice were housed in cages with autoclaved bedding and
equipped with ﬁlter caps under containment protocols with up
to ﬁve animals per cage. A 12-h light/dark cycle was maintained,
and mice had access to water and rodent laboratory chow ad
libitum.
The ethics committee approved this whole study, including
work on human samples as well as work on mice.
RESULTS
CONSTRUCTION AND EXPRESSION OF RECOMBINANT PROTEINS
In order to test our hypothesis, we constructed the recombi-
nant fusion protein FBD3 that contains the bacterial protein
ﬂagellin and the anti-bacterial peptide BD3. We used the full
coding sequence of the gene ﬂic from Salmonella typhimurium
(aa 1–495) and the sequence of the human BD3, containing
45 amino acids of the mature peptide. The nBD3 was cloned
5′ to the ﬂagellin sequence. We also constructed each moiety
separately: ﬂagellin (F) and nBD3. Apart from nBD3, the recom-
binant proteins were constructed with a Histidine (HisX6) tag at
their N′ terminus. Figure 1A represents the schematic structures
of the recombinant proteins/peptide and their expected molecular
weights. All clones were expressed in several E. coli bacterial strains
and under different conditions to obtain high expression levels.
Upon expression, bacterial cells were disrupted and cellular sub-
fractions were prepared, separating the soluble and non-soluble
fractions. SDS-PAGE and Western blot analysis using anti-His or
anti-beta defensin 3 antibodies demonstrated that the recombi-
nant proteins were found mostly in the soluble fraction (results
not shown).
Next we puriﬁed the various proteins using afﬁnity chromatog-
raphy (for FBD3 and F) and ion exchange (for nBD3 and F;
Figures 1B,C). To remove endotoxin from the puriﬁed F protein,
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FIGURE 1 |The FBD3 fusion protein and the separate components;
schematic presentation and purification. (A) Schematic representation of
ﬂagellin β-defensin-3 (FBD3) fusion protein, ﬂagellin (F) and the native BD3
(nBD3) lacking the His-Tag. (B) SDS-PAGE (upper image) and Western blot
using anti-His antibodies (lower image) to analyze the puriﬁcation steps of
FBD3 using afﬁnity chromatography as described in Methods. (C) SDS-PAGE
of puriﬁcation steps of F using afﬁnity chromatography as described in
Methods and using ion exchange chromatography (D) as described in
Methods. The chosen resin for F puriﬁcation is marked by a square.
(E)Tricine gel and Western blot using anti-BD3 antibodies analysis of nBD3
puriﬁcation steps using ion exchange chromatography as described in
Methods. M, marker; W.C, whole cell extract; Sol, soluble fraction; InSol,
insoluble fraction; Samp, sample; FT1/2, ﬂow through1/2; U.b, unbound
fraction; B, bound fraction; DEAE, diethylaminoethyl weak anion; SP,
sulphopropyl strong cation; Q, quaternary amine strong anion, U.Ind,
Un-induced fraction.
an additional puriﬁcation step was performed using various ion
exchange resins and buffers. As can be seen in Figure 1D, the SP
resin gave the best results; while most of the undesired proteins
did not bind to the resin, the F protein did bind to it (marked by
a square).
To purify the nBD3 peptide, which lacked the His-Tag, we used
conventional puriﬁcation methods. Western blot analysis using
anti-His (Figure 1B, lower image) or anti BD3 (Figure 1E; lower
image) conﬁrmed the identity of the FBD3 fusion protein and
nBD3 peptide, respectively.
FBD3, nBD3, AND F IN VITRO ACTIVITY
Antibacterial activity of nBD3 and FBD3
To analyze the antibacterial activity of the nBD3 peptide and the
FBD3 fusion protein, we developed an in vitro assay that tests
their effect on the CFU of different strains of growing bacte-
ria. Cell survival was calculated by comparing the number of
CFU of bacterial cells treated with the nBD3 peptide or the
FBD3 fusion protein to those of control bacterial cells. We found
that nBD3 was highly active and very efﬁciently killed E. coli
bacteria (DH5α) in a dose-dependent manner. At the highest
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FIGURE 2 | In vitro anti-bacterial activity of nBD3 peptide. (A,B) In vitro
anti-bacterial activity of nBD3 peptide against Escherichia coli (DH5α) bacteria
– dose dependency. Antibacterial activity of the nBD3 peptide with increasing
concentrations of the peptide. (B)The results in graphic presentation. One
representative experiment out of four performed is shown. Variations were
±5%. (C–E) Kinetics of nBD3 peptide (100 μg/ml) anti-bacterial activity
against DH5α E. coli bacteria. (C,D) In vitro antibacterial activity of the nBD3
peptide after 0.5, 1, 2, and 3 h against E. coli bacteria. (E) Graphic
presentation of the results in (C,D). One representative experiment out of
three performed is shown. Variations were ± 5%. (F,G)The nBD3 peptide has
speciﬁc antibacterial activity against E. coli bacteria. (F) Effect of nBD3 and
controls on bacterial growth. (G) Graphic presentation of results presented
in (F). Control: 20 mMTris pH 8. Clone +IPTG: native BD3 peptide expressed
in Codon+ BL21 E. coli. Clone –IPTG: Codon+ BL21 E. coli transformed with
the plasmid for the BD3 peptide but without induction with IPTG. Bacteria
+IPTG: Codon+ BL21 E. coli with induction of IPTG but without clone. One
representative experiment out of four performed is shown. Variations were
±5%.
concentration (100 μg/ml) nBD3 decreased the survival rate to
<0.2% (Figures 2A,B).
Next we tested the kinetics of the peptide action. We found
that the antibacterial activity of nBD3 is time-dependent and
after 3 h incubation, most of the bacteria did not survive
(Figures 2C–E).
In order to conﬁrm that the measured anti-bacterial activity
is a result of the peptide’s action and not caused by non-speciﬁc
activity of the puriﬁed peptide’s preparation,we used two controls:
the ﬁrst was a soluble fraction of E. coli BL21 Codon+ that was
grown without the plasmid of the nBD3 clone (marked as bacteria
+IPTG). This fraction was expressed and puriﬁed under the same
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FIGURE 3 | In vitro anti-bacterial activity of nBD3 peptide and control
samples against different bacterial strains. In vitro anti-bacterial activity of
the nBD3 peptide (100 μg/ml) against: E. coli ATCC 25922 (A),
Staphylococcus aureus ATCC 6538 (C) and Salmonella typhimurium ATCC
14028 (E). (B,D,F) Graphic presentations of results presented in (A,C,E),
respectively. One representative experiment out of four performed is shown.
conditions as were used for the nBD3. The second control was
a soluble fraction of E. coli BL21 Codon+ that was grown with
the plasmid of the nBD3 clone but without the inducer, IPTG
(marked as Clone −IPTG). This sample was also expressed and
puriﬁed under the same conditions as were used for the native
peptide. As seen in Figures 2F,G, at 100 μg/ml of the different
tested samples, only nBD3 (marked as clone +IPTG) had antibac-
terial activity and caused a decrease of 93% in the CFU, while the
two control samples (Bacteria –IPTG and Clone –IPTG) showed
no anti-bacterial killing activity.
We also tested the antibacterial activity of nBD3 on other
strains of bacteria. We chose the following bacterial strains:
E. coli (ATCC 25922); a pathogenic recommended and widely
used gram-negative bacterium for antibiotic susceptibility assays.
Staphylococcus aureus (ATCC 6538), which are pathogens of
humans and other mammals. Salmonella typhimurium (ATCC
14028), a gram-negative bacterium causing systemic infections
and typhoid fever in humans.
We found that the nBD3 could kill pathogenic E. coli (ATCC
25922) and Staphylococcus aureus (ATCC6538) but not Salmonella
typhimurium (ATCC 14028; Figures 3A–F). The control samples
(Bacteria –IPTG and Clone –IPTG) showed no killing activity
against the pathogenic E. coli and Staphylococcus aureus bacterial
strains (Figures 3A–F), conﬁrming its speciﬁc anti-bacterial
activity.
In order to examine whether the FBD3 fusion protein pos-
sesses the antibacterial activity of the BD3 moiety, we used the
in vitro antibacterial activity assay. It should be pointed out that
the peptide moiety is 10-fold smaller than the ﬂagellin protein,
a fact that could be a limiting factor for its antibacterial activ-
ity. As seen in Figures 4A–F, the antibacterial moiety of FBD3
has activity against pathogenic E. coli and the survival rate of
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FIGURE 4 | In vitro anti-bacterial activity of the FBD3 fusion protein.
(A,C,E) Antibacterial activity of three different expressions of puriﬁed FBD3
(0.2 mg/ml) against pathogenic E. coli (ATCC 25922). (B,D,F) represent the
results of (A,C,E) respectively, in graphs. (G–J) Antibacterial activity at
increasing concentrations of FBD3 in PBS with 10 mM DTT (G) or 50 mM
DTT (I). (H,J) represent the results of (G,J) respectively, in graphs. One
representative experiment out of four performed, is shown. Variations were
±5%.
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FIGURE 5 | In vitro activity of F and FBD3 proteins-secretion of IL-8.
(A,B) FACS analysis of Toll-Like-Receptor-5 on Colo-205 and Bjab cell lines.
(C,D) In vitro activity of the F protein on Colo-205 and Bjab cells.
Colo-205 or Bjab cells (105 cells/ml) were incubated with 20 ng (protein)
of F for 4 h. The medium separated from the various samples was tested
and the amount of the IL-8 was measured as described in Methods. One
representative experiment out of two performed is shown (C). Variations
were ±10%. Colo-205 cells (105 cells/ml) were incubated with different
concentrations of F (1.2 and 12 ng protein), FBD3 (2 or 20 ng fusion
protein; comprising about 1.8 and 18 ng, respectively, of the F protein)
and GnRH-Cherry for 4 h (20 ng protein). The medium from the different
samples was analyzed and the amount of the IL-8 was measured by an
Elisa assay as described in the “Methods.” One representative
experiment out of four performed is shown (D).
the bacteria was 20–40% when we added 0.2 mg/ml of FBD3
fusion protein (comprising about 20 μg/ml of the BD3 peptide
component). However, although it had antibacterial activity in
vitro, we encountered difﬁculties in obtaining biologically active
and reproducible FBD3-fusion protein preparations. As already
mentioned, defensin peptides have three intermolecular disulﬁde
bonds. Based on site-directed mutagenesis studies, these bonds
are not essential for the antibacterial activity of the peptide but
are important for peptide stability and its chemotactic activity
(Hoover et al., 2003; Wu et al., 2003). In an attempt to resolve
these problems, we dialyzed the FBD3 against PBS in the pres-
ence of 10 mM or 50 mM DTT. As seen in Figures 4G–J, the
fusion proteins that were dialyzed in the presence of DTT exhib-
ited antibacterial activity and killed bacteria in a dose-dependent
manner. At the highest concentration (1 mg/ml; comprising about
100 μg/ml of the BD3 peptide component), the FBD3 fusion
protein decreased the bacterial survival rate to 5%.
The FBD3 fusion protein and the F protein exhibit ﬂagellin biological
activity
Next we tested the ﬂagellin moiety. In order to examine the bio-
logical activity of the ﬂagellin, we designed an in vitro assay that
measures one of ﬂagellin’s activities – secretion of a chemokine
upon binding to its TLR5 receptor. Based on the literature, colon
cancer cells highly express TLR5 and can secrete the chemokine
IL-8 upon stimulation with ﬂagellin, while B cells express the
receptor but cannot secrete this chemokine (Schmausser et al.,
2005). To test the sensitivity of this assay, the expression of
TLR5 was examined in a number of cell lines by FACS analy-
sis. We found that colo-205 and Bjab cell lines do indeed highly
express TLR5 (97%; mean: 127 and 96%; mean: 123 respec-
tively; Figures 5A,B). To measure the levels of IL-8 secreted
upon F stimulation, we used an ELISA kit for human IL-8. As
seen in Figure 5C, colo-205 cells that were incubated for 4 h
with 20 ng of the puriﬁed F protein secreted the chemokine
IL-8, while Bjab cells did not secrete any detectable levels of
IL-8.
Next we tested the activity of the ﬂagellin moiety in the fusion
protein FBD3. As seen in Figure 5D, FBD3 could trigger colo-
205 cells to secrete IL-8 and its activity was dose-dependent,
similar to the activity of the F protein (Figure 5D). A control
protein, GnRH-Cherry, lacking the ﬂagellin protein, expressed
and puriﬁed under the same conditions as FBD3 and F, could not
trigger these cells to secrete IL-8 even at high doses of the pro-
tein (Figure 5D). Moreover, addition of both FBD3 fusion protein
and the F protein to cells negative for the expression of TLR5
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receptor, could also not trigger these cells to secrete IL-8 (results
not shown). Thus, the activity of the ﬂagellin moiety of FBD3 is
speciﬁc.
FLAGELLIN PARTIALLY PROTECT MICE FROM BACTERIAL INFECTION
In order to test the ability of our proteins to protect mice from
bacterial infection, puriﬁed F (5 or 10 μg), FBD3 (20 μg), or PBS
(control, in equal volume) was injected into 7–8 week old female
Balb/C mice, for a preliminary study. Four hours after i.p. injec-
tions of proteins/PBS, 100 μl of 5 × 108 CFU/ml of pathogenic
E. coli bacteria were injected i.p. into these mice. Mouse survival
was followed over the next few days. As seen in Figure 6A, the
F protein conferred a partial protective effect for the bacteria-
infected mice. After 4 days the survival rate of the mice in the
control group was 12.5% while the survival rate of the mice,
which had received 5, or 10 μg of the F protein was 37.5 and
40% respectively.
As seen in Figure 6B, 20 μg FBD3 also had a partial protective
effect on mice infected with pathogenic E. coli bacteria. No mice
survived after day two in the control group, while the survival
FIGURE 6 | Partially protective effect of F and FBD3 proteins on mice
infected with pathogenic E. coli bacteria. Seven to eight week old
female Balb/C mice were injected i.p with puriﬁed F protein (5 μg; 8 mice
or 10 μg; 10 mice) (A) or FBD3 fusion protein (20 μg; 10 mice) (B). After 4 h
100 μl of 5 × 108 CFU/ml of E. coli bacteria was injected i.p. into the mice.
Mouse mortality was determined over the next 5 or 6 days. Control
represents infected mice that received only PBS (in equal volume); each
control group consisted on eight mice.
rate of the treatment group remained at 20% for the next ﬁve
days. These very preliminary results indicate a potential partially
protective effect of F and FBD3 proteins in bacteria-infected mice.
THE MECHANISM OF FLAGELLIN’S ACTION ON CD4+ T CELLS
To reveal some basic aspects of ﬂagellin’s action via its receptor,
TLR5, we used mononuclear cells from healthy humans. We chose
to test the effect of ﬂagellin on the CD4+ T cell subpopulation,
which has been suggested to be a bridge between the innate and
the adaptive immune system through the TLR5 receptor expressed
on these cells.
To test the events following ﬂagellin stimulation, we used real
timePCR to follow changes inmRNA levels of several genes known
to play central roles in immune processes. CD4+ T cells were
isolated fromperipheral blood of healthy donors by afﬁnity puriﬁ-
cation, using CD4 magnetic beads. We ﬁrst checked the isolated
CD4+ T cells for the expression of TLR5 using FACS analysis and
found that 96% (mean: 129) of naïve CD4+ T cells express the
TLR5 receptor (results not shown).
The immune system reaction – cytokine proﬁle
Flagellin affects naïve CD4+ T cells but not activated CD4+ T
cells. In order to test the cytokine proﬁle upon ﬂagellin stimu-
lation, naïve CD4+ T cells were isolated from peripheral blood
of healthy donors and triggered with F protein for various time
periods (Figure 7A). We found that INFγ-mRNA levels increased
by 3.4-fold after 18 h and by 2.4-fold after 24 h, as compared
to control un-stimulated cells (Figure 7C). We also found that
IL12A-mRNA increased by 2.5-fold after 18 h and by 3.5 after
24 h (Figure 7C). The mRNA levels of the genes for IL4 and IL5 in
control, untreated samples were too low to allow calculation of the
changes in the mRNA levels but based on the cycle’s number in the
real time PCR analysis, we estimated that there was no change in
the mRNA levels of these genes upon ﬂagellin stimulation (results
not shown). Thus, ﬂagellin stimulation caused the CD4+ T cells
to increase the mRNA levels of IL12A and IFNγ, the cytokines
associated with the Th1 response.
Next we tested the effect of ﬂagellin on activated CD4+ T cells.
Whole mononuclear cells were isolated from peripheral blood of
healthy donors, activated by PHA for 72 h and then grown in the
presence of IL2 (10 units/ml recombinant IL-2) to maintain the
activated phenotype. Activated CD4+ T cells were then isolated
using CD4 magnetic beads and stimulated with ﬂagellin for 24 or
48 h (Figure 7B). In the activated CD4+ T cells, the mRNA levels
of the genes for IL12A and INFγ did not change upon ﬂagellin
stimulation (Figure 7C).
The impact of the “neighbor cells” on cytokine proﬁle after ﬂag-
ellin stimulation. The expression of TLR5 has been described for
many cell populations of the immune system in addition to T cells.
These cells produce a variety of cytokines that may inﬂuence the
CD4+ T cells. Because CD4+ T cells are not alone in vivo, we
took whole mononuclear cells (after ﬁcoll gradient) and stimu-
lated them with F in an attempt to mimic the natural environment
of T cells in the body. This allowed us to examine the contribution
of “neighbor-cells” to the expression level of the different cytokines
in CD4+ T cells, upon ﬂagellin stimulation.
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FIGURE 7 | Continued
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FIGURE 7 | Continued
Effect of F protein on expression levels of IL12A and IFNγ in CD4+T
cells from healthy donors. (A–C) Effect of F protein on expression levels
of IL12A and IFNγ in naïve and activated CD4+T cells. (A) Experimental
design for naïve cells – CD4+T cells were isolated from peripheral blood of
healthy donors using CD4+ magnetic-beads. CD4+T cells were seeded
and incubated with the F protein (2 μg/ml) for 18 or 24 h. (B) Experimental
design for activated cells – mononuclear cells were activated by PHA
(20 μg/ml) for 72 h and then grown with IL2 (10 units/ml recombinant IL-2).
Following activation, CD4+T cells were separated using CD4 magnetic
beads. CD4+T cells were seeded and incubated with the F protein (2 μg/ml)
for 24 or 48 h. Following the incubation, cDNA samples were prepared and
subjected to real-time-PCR analysis using SYBR green reagent (as described
in Methods). (C) Changes in IFNγ-mRNA and IL12A-mRNA levels upon F
stimuli, compared to control cells. I = one F stimulation. Data represents
the mean ± SD of 3–5 separate experiments. (D,E) Effect of the F protein
on expression levels of IL12A and IFNγ in naïve CD4+T cells after triggering
all mononuclear cells. (D) Experimental design – Naïve mononuclear cells
were incubated with ﬂagellin for different time periods, after which CD4+T
cells were separated using CD4 magnetic beads. The separated CD4+T
cells were taken and cDNA samples were prepared and subjected to real
time-PCR analysis using SYBR green reagent (as described in Methods).
(E)The changes of IFNγ-mRNA and IL12A-mRNA in CD4+T cells levels
upon ﬂagellin stimuli in the presence of mononuclear cells after 2, 6, 12, 24,
and 36 h. I = one F stimulation. Data represents the mean ± SD of 3–5
separate experiments. (F,G) Effect of the F protein on expression levels of
IL12A and IFNγ in naïve CD4+T cells after triggering the mononuclear cells
three times. (F) Experimental design – Naïve mononuclear cells were
triggered three times with ﬂagellin for 2 or 12 h stimuli. Following
stimulation, CD4+T cells were separated using cd4 magnetic beads. The
separated CD4+T cells were removed and cDNA samples were prepared
and subjected to real time PCR analysis using SYBR green reagent (as
described in Methods). (G) Changes of IFNγ- and IL12A mRNA levels upon
repeated ﬂagellin stimulations for 2 or 12 h each. III = three F stimulations.
Data represents the mean ± SD of 3–5 separate experiments.
We triggered whole mononuclear cells with ﬂagellin for 2, 6,
12, 24, and 36 h, then separated CD4+ T cells and isolated RNA
to measure the expression levels of speciﬁc genes (Figure 7D).
As seen in Figure 7E, stimulation with F protein for 2 h caused
the mRNA levels of cytokines IL12A and INFγ to increase by
1.66 and 1.94-fold, respectively. After 6 h the increase was even
more signiﬁcant with the levels of IL12A-mRNAand INFγ-mRNA
increasing by 5.5 and 4.6-fold, respectively, and staying unchanged
for up to 12 h. A prolonged 24 h exposure to ﬂagellin caused
a more dramatic increase in the expression of both genes, with
IL12A-mRNA increasing by 7.6-fold and INFγ-mRNA increas-
ing by 9.6-fold. 36 h of ﬂagellin stimulation caused a higher
increase in INFγ-mRNA of 15-fold, whereas the IL12A-mRNA
levels decreased and were only 3.2-fold higher than in control cells
(Figure 7E).
As seen in Figure 7E, long exposure to F protein (36 h) in the
presence of all mononuclear cells caused a dramatic increase in
the IFNγ-mRNA levels in CD4+ T cells. To examine this phe-
nomenon more closely, we triggered all mononuclear cells three
times with F protein (Figure 7F) and measured the levels of IFNγ
and IL12A mRNAs. We found that three, 2-h stimulations, caused
an increase in the mRNA levels of IFNγ and IL12A by 4.4 and
by 5.1-fold, respectively (Figure 7G). Three, 12-h stimulations
with F protein caused a dramatic increase in the mRNA levels
of IFNγ of 78-fold when compared to non-treated cells. The
increase of the IL12A mRNA under these conditions was 3.3-fold
(Figure 7G).
FLAGELLIN AFFECTS TLR5 mRNA LEVELS IN NAÏVE CD4+ T CELLS BUT
NOT IN ACTIVATED CD4+ T CELLS
In order to examine whether ﬂagellin has an inﬂuence on its own
receptor TLR5, naive CD4+ T cells were isolated from peripheral
blood of healthy donors and triggered with F protein for various
time periods (see Figure 7A). We found that upon F stimulation
the levels of the TLR5-mRNA increased by 1.8-fold after 18 h
and 2.2-fold after 24 h as compared to control, unstimulated cells
(Figure 8A).
Next, we tested whether ﬂagellin triggering has the same effect
on activated CD4+ T cells. CD4+ T cells were isolated from
peripheral blood of healthy donors that was activated with PHA
for 72 h (Figure 7B). Following activation the cells were stimu-
lated with ﬂagellin for different time periods. As seen in Figure 8B,
stimulation with F protein for 24 or 48 h did not cause any signiﬁ-
cant increase in TLR5-mRNA levels in the activated CD4+ T cells.
These ﬁndings are in correlation with our previous results regard-
ing cytokines’ mRNA levels, showing that ﬂagellin only affects the
naïve CD4+ T cells (Figure 7).
The impact of continued ﬂagellin stimulation on TLR5 mRNA levels
in CD4+ T cells
We ﬁrst tested isolated naïve CD4+ T cells. As opposed to a sin-
gle trigger with F that caused an increase in the mRNA levels of
TLR5, repeated stimulations for 12 h caused a twofold decrease in
the TLR5-mRNA levels (Figure 8C). Activated CD4+ T cells, on
the other hand, had slightly increased TLR5-mRNA levels upon
repeated stimulations with F protein. Three stimulations of F, each
for 12 or 24 h, caused an increase in the TLR5-mRNA levels by
1.8- and 1.5-fold respectively, as seen in Figure 8D.
These results indicate that naïve and activated CD4+ T cells
react differently to ﬂagellin triggering with respect to expression
of the TLR5 receptor. We also observed that naïve cells are more
sensitive to ﬂagellin stimulation than activated cells; while naïve
CD4+ T cells increased their mRNA levels after one stimulus,
activated CD4+ T cells needed three stimulations to respond in a
similar manner.
Neighboring cells have an impact on TLR5-mRNA levels in CD4+ T
cells after ﬂagellin stimulation
To test the impact of the neighboring cells on TLR5 regulation
in CD4+ T cells, we used the total fraction of mononuclear cells
and triggered them with F protein for various time periods (see
Figure 7D). As seen in Figure 8E, 2 h of stimulation did not
change the level of TLR5-mRNA but stimulation for 6 h increased
theTLR5-mRNAby 2.8-fold a level atwhich it remained for at least
12 h. However, prolonged exposure to F protein caused the oppo-
site result; 24 h of stimulation decreased the levels of TLR5-mRNA
by 50%, with an even more signiﬁcant decrease after 36 h of stim-
ulation, of 3.5-fold lower than control untreated cells (Figure 8E).
TLR5 AND INFγ – IS THERE ANY CONNECTION?
An interesting connection between INFγ-mRNA levels and the
TLR5-mRNA levels in CD4+ T cells was observed upon ﬂagellin
stimulation. Moderate levels of INFγ-mRNA were detected with
increasing levels of TLR5-mRNA levels; however high levels of
INFγ-mRNA were detected when the levels of TLR5-mRNA were
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FIGURE 8 | Effect of the F protein on expression levels ofTLR5 in healthy
CD4+T cells. (A,B) Changes of TLR5-mRNA levels in naïve (A) or activated
(B) CD4+T cells upon one F stimulation after 18 or 24 h. (C,D) Changes of
TLR5-mRNA levels following repeated (three) F stimulations in naïve (C) and
activated (D) CD4+T cells. (E) Changes of TLR5-mRNA levels following one F
stimulation after various incubation times. Data for each graph represents the
mean ± SD of 3–5 separate experiments (A,B,E) or one representative
experiment out of two performed is shown (C,D).
very low (Figure 9). These results suggest a possible role of INFγ
in the regulation of TLR5.
DISCUSSION
One major concern in medicine today is the growing resistance
to antibiotic treatment as a result of their widespread and inten-
sive use (Spellberg et al., 2008) that has dramatically increased the
emergence of resistant pathogens. The major threat is the spread
of a virulent bacterium that is resistant to all antibacterial agents
available today.
In this work we propose an innovative approach to ﬁght bac-
terial infections based on the use of two components: the human
antibacterial peptide BD3 that belongs to the innate immune sys-
tem and the bacterial protein ﬂagellin that induces the immune
system. This combination was designed to provide an efﬁcient
weapon to attack bacterial infections; while the peptide kills the
bacteria directly, the ﬂagellin protein should trigger the immune
system and act against residual bacteria that succeed in escap-
ing the peptide’s action. In order to test this concept we used
two strategies; the ﬁrst was to design a fusion protein (FBD3)
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FIGURE 9 | Possible connection between theTLR5- and IFNγ-mRNA
levels following flagellin stimulation. Comparing expression levels of
TLR5-mRNA to those of IFNγ-mRNA at different F protein stimulation
conditions. Data represents the mean ± SD of three separate experiments.
containing both molecules on one single polypeptide. The second
strategy was to design the two components as separate molecules
and use them either separately or in a combination.
We designed, expressed and puriﬁed the fusion protein FBD3,
the recombinant protein F and the nBD3 peptide (Figure 1). We
found that both the FBD3 fusion protein and the nBD3 peptide
had antibacterial activity in vitro against several different bacte-
rial strains [E. coli (DH5α), pathogenic E. coli (ATCC 25922), and
Staphylococcus aureus (ATCC 6538)]; however with different efﬁ-
cacies (Figures 2 and 4). We also demonstrated that the ﬂagellin
moiety of FBD3 and the recombinant F protein, most probably,
recognize their receptor, TLR5, which is expressed on target cells
and conﬁrmed their ability in vitro to speciﬁcally stimulate secre-
tion of IL-8 (Figure 5). The F and FBD3 proteins were tested for
their biological activity in an in vivo mice model; we showed that
these proteins have a partial protective effect on mice infected by
pathogenic E. coli bacteria that cause a lethal disease (Figure 6).
In addition, we analyzed some basic mechanisms through which
the F protein may be act, focusing on human CD4+ T cells from
healthy donors.
The use of antibacterial peptides as therapeutic tools is limited
since most of the peptides do not work at physiological con-
centrations of NaCl (Dhople et al., 2006). Additional limitations
are the instability of the peptides and their toxicity for the host
cells (Jenssen et al., 2006). However, the human BD3 is partic-
ularly attractive due to its strong antibacterial activity, relative
salt-insensitiveness and low toxicity for host cells (Batoni et al.,
2006). Indeed, nBD3 exhibits dose dependent antibacterial activ-
ity against a number of bacterial pathogenic strains (Figures 2 and
3). It should be pointed our that in our research, we cloned the
nBD3 peptide without a tag and demonstrated that the puriﬁed
peptide exhibited antibacterial activity (Figure 2). It should be
emphasized that the expression of antibacterial peptides in bacte-
rial expression systems is mostly achieved by tagging the peptide
with various tags that are eventually cut out following expression
and puriﬁcation (Corrales-Garcia et al., 2011). The insertion of a
tag to the peptide is done in order to protect the bacterial cells
from toxic effects of the antibacterial peptide they are expressing.
We decided to express the peptide without any tag due to the fact
that most of the antibacterial peptide activity models suggest that
the peptide works on the outer bacterial membrane (Brogden,
2005). The fact that we could express an active soluble peptide
in a bacterial host was surprising and is in agreement with the
proposed models of its activity (Brogden, 2005).
Flagellin and FBD3 proteins showed only a partial protective
effect of about 20% in mice infected by pathogenic E. coli bac-
teria (Figure 6). This might be explained by the very severe and
lethal infection induced in this model, as indicated by the very low
(Figure 6A) or no survival (Figure 6B) of mice in the control, non-
treated mice. We suggest that in a follow-up research, the efﬁcacy
of the F and FBD3 proteins should be tested in vivo on a much
milder bacterial infection. In addition, experiments performed
were preliminary, using only one bacterial strain (pathogenic E.
coli) injected i.p. into mice as a route for inducing an infec-
tion. FBD3 and the F proteins should be tested in additional
in vivo models to fully evaluate their therapeutic and protective
potential.
However, It should be emphasized that we were able to show
partial protection of mice infected with a pathogenic E. coli
strain using a ﬂagellin sequence from Salmonella. The fact that
Salmonella ﬂagellin has a protective effect against Salmonella infec-
tion in mice has been previously published (Vijay-Kumar et al.,
2008). However, here we were able, to our knowledge for the ﬁrst
time, to protect mice from an E. coli infection using a ﬂagellin
sequence from Salmonella typhimurium. Our results thus suggest
that the protective effect was most probably due to the activation
of the innate immune system. The immediate and very fast pro-
tective response provides further ﬁndings supporting the idea that
activation of the innate immune system was responsible for the
protection (Figures 6A,B).
Moreover, our results suggest that ﬂagellin or its derivatives
such as FBD3 activate the innate immune response, and so may
be used to treat bacterial infections. The innate immune response,
in contrast to the adaptive response, is not speciﬁc to one speciﬁc
antigen, so the ability to design antibacterial agents that will trig-
ger only the innate immune system provides a breakthrough in
medicine due to its broad spectrum of protection.
Nevertheless, to achieve a good and effective immune response,
the innate and the adaptive immune systems work in collabo-
ration. TLRs belong to the innate immune system, many cells
however belonging to the adaptive immune system also express
these receptors, suggesting thatTLRsmay serve as a bridge between
the two components of the immune system. CD4+ T cells are a
major subpopulation of cells that play a key role in the adap-
tive immune system and that express the TLR5. For this reason,
we chose to focus on CD4+ T cells from healthy donors and to
explore the effects of ﬂagellin via its receptor TLR5 on various
mechanisms.
As demonstrated by our results, only naïve CD4+ T cells
respond toﬂagellin stimulation (Figure 7). The stimulation caused
these cells to have increased mRNA levels of the cytokines IFNγ
and IL12A that are characteristic of the Th1 response (Figure 7).
However, a much more signiﬁcant effect was achieved when
we triggered the total mononuclear cell fraction with ﬂagellin
(Figure 7). Therefore, we suggest that ﬂagellin has, most probably,
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both a direct and indirect effect on the cytokine proﬁle in CD4+
cells.
Another interesting ﬁnding was the dramatic elevation in
the IFNγ-mRNA levels caused by repeated ﬂagellin stimula-
tions (Figure 7). IFNγ is major cytokine that plays a central
role in the immune response to infections (Saha et al., 2010).
One of the observations in chronic diseases is the down reg-
ulation of the zeta chain of the T cell receptor (TCR). This
phenomenon is related to sustained exposure to bacterial anti-
gens (Bronstein-Sitton et al., 2003). TLRs play a major role in
the induction of both the innate and the adaptive immune sys-
tem. Previous studies have shown that several agonists belonging
to the TLRs family lead to an immunosuppressive response;
one of the mechanisms that were suggested as being responsi-
ble for this phenomenon is the secretion of IFNγ (Vaknin et al.,
2008). These ﬁndings are relevant to our proposed approach,
as they indicate that the number of ﬂagellin stimulations will
need to be carefully considered if ﬂagellin therapy is further
developed.
Constant stimulation of the immune system can be harmful for
the host, with various inﬂammatory mediators causing damage
(Bronstein-Sitton et al., 2003). To regulate the immune response
many of the components of the immune system work through
a feedback loop that helps the system to regulate itself and pre-
vent autoimmune damage. Flagellin is a major antigen in many
infections that can trigger the immune response by activating its
receptor, TLR5 (Vijay-Kumar and Gewirtz, 2009). Therefore, we
decided to test whether ﬂagellin has a role in the regulation of
this receptor. We demonstrated that isolated naïve CD4+ T cells
triggered by ﬂagellin increased their TLR5-mRNA levels, while
activated CD4+ T cells did not respond (Figure 8). In addition,
the naïveCD4+T cells needed only one stimulus to respond,while
the activated cells responded only after three stimuli (Figure 8).
We also found that the neighboring cells have an effect on the
regulation of TLR5-mRNA in CD4+ T cells; while a brief ﬂag-
ellin exposure caused an increase in TLR5 mRNA levels, a long
exposure caused a decrease in the mRNA levels (Figure 8). From
these ﬁndings we can propose a feedback role for ﬂagellin in the
regulation of its own receptor, TLR5. Short exposure to ﬂagellin
causes an increase in the mRNA levels of TLR5 and activates the
immune response. To avoid continuing stimulation, long exposure
to ﬂagellin causes down regulation of the receptor. By this mecha-
nism the immune system response can be regulated, without being
self-damaging.
An additional interesting ﬁnding was the different response to
ﬂagellin seen in a isolated population of CD4+ T cells compared
to that seen with a mixture of all the mononuclear cells. While
isolated naïve CD4+ T cells exposed to ﬂagellin for 24 h showed
an increase in their mRNA levels, exposing total mononuclear cells
to ﬂagellin caused a decrease in the mRNA levels of TLR5 in the
CD4+ T cells (Figure 8). We suggest that ﬂagellin regulates TLR5,
most probably, via both direct and indirect activity. In this regard,
we found an interesting connection between the levels of the IFNγ
and the levels of TLR5 upon ﬂagellin stimuli; low levels of the
TLR5 were detected when very high levels of IFNγ were measured
(Figure 9). IFNγ is known to regulate the expression of a number
of genes including MHCI genes, TLR3, STAT3, and many others
(Saha et al., 2010). Thus, we suggest that IFNγ may have role in
the regulation of the TLR5 gene.
We found that the ﬂagellin moiety in the FBD3 fusion pro-
tein did not loss its activity and had high activity on colo-205
cells in vitro as the separate F protein (Figure 5). The observa-
tion that ﬂagellin did not lose its function in the fusion protein is
important for designing new additional fusion proteins based on
ﬂagellin.
For the antibacterial activity, our results indicated that nBD3
was active in vitro (Figures 2 and 3). The fusion protein was more
difﬁcult to produce. However, with regard to the use of the fusion
protein, we also need to consider a molecule that contains a ﬂag-
ellin sequence lacking the hypervariable region. In addition to
the lower toxicity of its ﬂagellin moiety, this fusion protein will be
smaller in size and thismay prevent its negative impact on the pep-
tide’s action. Thus we believe that both approaches, that of using
the FBD3 fusion protein and that of utilizing the separate com-
ponents, the F protein and the nBD3 peptide, should be further
investigated and developed.
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